Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Long-term Extension of the ARGX-117-2002 Trial to Evaluate the Long-term Safety and Tolerability, Efficacy, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of ARGX-117 in Adults With Multifocal Motor Neuropathy

NCT05405361 is registered in ClinicalTrials.gov with argenx as lead sponsor.

NCT NCT05405361
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05405361 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Long-term Extension of the ARGX-117-2002 Trial to Evaluate the Long-term Safety and Tolerability, Efficacy, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of ARGX-117 in Adults With Multifocal Motor Neuropathy
Lead sponsor
argenx
Phase
Phase 2
Overall status
Active, not recruiting
Start date
January 18, 2023
Completion date
September 30, 2029
Enrollment
51 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

multifocal motor neuropathy (mmn)